The effects of centrally acting ACE inhibitors on the rate of cognitive and functional decline in dementia: a KDD approach

dc.check.embargoformatNot applicableen
dc.check.infoNo embargo requireden
dc.check.opt-outNoen
dc.check.reasonNo embargo requireden
dc.check.typeNo Embargo Required
dc.contributor.advisorMolloy, D. Williamen
dc.contributor.advisorSammon, Daviden
dc.contributor.authorGao, Yang
dc.date.accessioned2016-05-25T16:39:10Z
dc.date.available2016-05-25T16:39:10Z
dc.date.issued2014
dc.date.submitted2014
dc.description.abstractAlzheimer’s Disease and other dementias are one of the most challenging illnesses confronting countries with ageing populations. Treatment options for dementia are limited, and the costs are significant. There is a growing need to develop new treatments for dementia, especially for the elderly. There is also growing evidence that centrally acting angiotensin converting enzyme (ACE) inhibitors, which cross the blood-brain barrier, are associated with a reduced rate of cognitive and functional decline in dementia, especially in Alzheimer’s disease (AD). The aim of this research is to investigate the effects of centrally acting ACE inhibitors (CACE-Is) on the rate of cognitive and functional decline in dementia, using a three phased KDD process. KDD, as a scientific way to process and analysis clinical data, is used to find useful insights from a variety of clinical databases. The data used are from three clinic databases: Geriatric Assessment Tool (GAT), the Doxycycline and Rifampin for Alzheimer’s Disease (DARAD), and the Qmci validation databases, which were derived from several different geriatric clinics in Canada. This research involves patients diagnosed with AD, vascular or mixed dementia only. Patients were included if baseline and end-point (at least six months apart) Standardised Mini-Mental State Examination (SMMSE), Quick Mild Cognitive Impairment (Qmci) or Activities Daily Living (ADL) scores were available. Basically, the rates of change are compared between patients taking CACE-Is, and those not currently treated with CACE-Is. The results suggest that there is a statistically significant difference in the rate of decline in cognitive and functional scores between CACE-I and NoCACE-I patients. This research also validates that the Qmci, a new short assessment test, has potential to replace the current popular screening tests for cognition in the clinic and clinical trials.en
dc.description.statusNot peer revieweden
dc.description.versionAccepted Version
dc.format.mimetypeapplication/pdfen
dc.identifier.citationGao, Y. 2014. The effects of centrally acting ACE inhibitors on the rate of cognitive and functional decline in dementia: a KDD approach. PhD Thesis, University College Cork.en
dc.identifier.endpage280en
dc.identifier.urihttps://hdl.handle.net/10468/2626
dc.language.isoenen
dc.publisherUniversity College Corken
dc.rights© 2014, Yang Gao.en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en
dc.subjectDementiaen
dc.subjectAlzheimer’s diseaseen
dc.subjectCentrally acting angiotensin converting enzyme inhibitorsen
dc.subjectKnowledge discoveryen
dc.subjectData analysisen
dc.subjectQmcien
dc.thesis.opt-outtrue
dc.titleThe effects of centrally acting ACE inhibitors on the rate of cognitive and functional decline in dementia: a KDD approachen
dc.typeDoctoral thesisen
dc.type.qualificationlevelDoctoralen
dc.type.qualificationnamePHD (Business Information Systems)en
ucc.workflow.supervisorw.molloy@ucc.ie
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Abstract.pdf
Size:
9.38 KB
Format:
Adobe Portable Document Format
Description:
Abstract
Loading...
Thumbnail Image
Name:
Yang thesis_final.pdf
Size:
8.25 MB
Format:
Adobe Portable Document Format
Description:
Full Text E-thesis
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
5.62 KB
Format:
Item-specific license agreed upon to submission
Description: